Medexus Pharmaceuticals Announces Resubmission of Treosulfan NDA
22.04.2022 - Additional data collection and analysis reconfirms confidence in New Drug Application for TreosulfanNDA resubmission date consistent with previously announced timelineFDA decision still expected within six months of resubmission TORONTO and ... Seite 1
Source: wallstreet-online.de